BMS-777607 is a selective and potent small-molecule met kinase inhibitor. Overexpression of c-Met receptor tyrosine kinase has been highly associated with prostate cancer progression and metastasis. BMS-777607 suppressed HGF-stimulated cell migration and invasion in a dose-dependent fashion (IC50 < 0.1 μmol/L). Mechanistically, nanomolar doses of BMS 777607 potently blocked HGF-stimulated c-Met autophosphorylation and downstream activation of Akt and extracellular signal-regulated kinase.
|Source||Mol Oncol (2014). Figure 2. BMS-777607|
|Cell Lines||breast cancer cells|
|Incubation Time||72 h|
|Results||Thus, results demonstrate that expression of p21/WAF1 and survivin is up-regulated in BMS-777607 induced polyploid/senescent cells regardless the status of p53.|
|Source||Mol Oncol (2014). Figure 1. BMS-777607|
|Method||senescence detection assay|
|Cell Lines||BMS-777607. T-47D and ZR-75-1 cells|
|Incubation Time||72 h|
|Results||The percentages of SABG-positive cells were associated with increased doses of BMS-777607.|
|Cell lines||PC-3 cell line|
|Preparation method||Cell proliferation and cell death Cells were seeded in a 96-well plate at a density of 5 × 103 cells per well and exposed to serial dilutions of BMS-777607 for 1 hour. HGF (25 ng/mL) was then added and the cells were incubated (drug plus HGF) for a period of 96 hours. At the end of the treatment period, the tumor cells were exposed to WST-8 (MTT assay reagent) in a Cell Counting kit (Donjindo Molecular Technologies) according to the manufacturer's instruction, and absorbance was determined at 450 nm colorimetrically. Cell proliferation (%) was calculated as the ratio of absorbance from treated sample to the nontreated control. Cell death was examined by trypan blue exclusion, and positively stained (dead) cells were scored using a hemocytometer.|
|Concentrations||0, 0.1, 0.3, 1, 3, 10 μM|
|Incubation time||96 h|
|Animal models||C3H/HeJ mice with KHT lung tumor model|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||DMSO 40 mg/mL|
 Schroeder et al. J Med Chem. Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily.
|Related c-Met Products|
BAY-474 is an inhibitor of tyrosine-protein kinase c-Met and can act as an epigenetics probe.
AMG-1 (c-Met/RON Dual Kinase Inhibitor, RON-IN-1) is a potent inhibitor of human c-Met and RON with IC50 of 4 nM and 9 nM, respectively.
JNJ-38877618 (OMO-1) is a potent, highly selective, orally bioavailable MET kinase inhibitor with binding affinity (Kd) of 1.4 nM and enzyme inhibitory activity against wt and M1268T mutant MET (2 and 3 nM IC50).
SAR125844 is a potent intravenously active and highly selective MET kinase inhibitor, displaying nanomolar activity against the wild-type kinase (IC50 value of 4.2 nmol/L) and H1094Y, Y1235D, M1250T, L1195V, and D1228H kinase domain mutants (IC50 values of 0.22, 1.7, 6.5, 65, and 81 nmol/L, respectively).
WAY-354831 is a inhibitor of c-Met kinase.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.